Treatment of young toddlers with peanut oral immunotherapy (OIT) may be the key to inducing remission of peanut allergy, a… Read more »
Phase 3 results from the European clinical trial of the Palforzia peanut OIT treatment show that desensitization to the allergenic… Read more »
A new study finds encouraging results for those considering the first FDA-approved peanut allergy immunotherapy. It reveals that clinical trial… Read more »
Allergists that Allergic Living contacted are excited about the FDA’s approval of the first-ever therapy for a food allergy. They… Read more »
The Food and Drug Administration on Jan. 31, 2020 approved Palforzia, Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for peanut allergy… Read more »
An expert advisory panel has recommended that the Food and Drug Administration approve Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for… Read more »
In its final report analyzing the costs and benefits of two novel peanut allergy desensitization products, the Institute for Clinical… Read more »
By extending the peanut biologic oral immunotherapy known as AR101 by 28 weeks, a new study finds that a majority… Read more »
Testing OIT in such a young population has never been done before, but results show that it’s worth it.
Two studies focused on peanut OIT have found possible answers to key research questions.